Literature DB >> 9296246

Management of drug interactions in patients with HIV.

A L Tseng1, M M Foisy.   

Abstract

OBJECTIVE: To provide a complication of relevant information on drug interactions to assist healthcare practitioners in managing complex HIV-related pharmacotherapy. DATA SOURCES: Information was retrieved via a MEDLINE search (January 1966-December 1996) using MeSH headings "human immunodeficiency virus," "drug interactions," and names of medications commonly prescribed for the management of HIV infection and related opportunistic infections. Abstracts of international and national conferences, review articles, textbooks, and references of all articles were also searched. STUDY SELECTION AND DATA EXTRACTION: All literature on pharmacokinetic or pharmacodynamic interactions was considered for inclusion. Pertinent information, as assessed by the authors, was selected and summarized for discussion. DATA SYNTHESIS: Drug disposition and/or pharmacologic effect may be affected either by HIV-related physiologic changes or by the presence of concomitant drug therapy. Modifications in drug selection, dosage, dosing regimen, or route of administration may be needed to avoid or manage drug-disease, drug-drug, or drug-food interactions. Management options may depend on the mechanism and the clinical significance of the interaction, the availability of therapeutic alternatives, patient convenience, and cost restrictions. In the absence of specific data, consideration of pharmacokinetic and pharmacodynamic characteristics to assist practitioners in predicting the likelihood of possible interactions was included.
RESULTS: A comprehensive table of clinically significant drug interactions is provided. Drug interaction principles and practical management strategies are also discussed.
CONCLUSIONS: The potential for drug interactions is extremely common, given the increasing complexity of managing patients infected with HIV. To avoid compromising therapeutic efficacy or increasing drug toxicity, practitioners need to be aware of potential interactions and are encouraged to use a systematic approach when managing patient drug therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9296246     DOI: 10.1177/106002809703100915

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  13 in total

1.  Re: The new macrolide antibiotics: Use them carefully.

Authors:  M Greenwald
Journal:  Paediatr Child Health       Date:  1998-07       Impact factor: 2.253

2.  Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.

Authors:  Samantha Abel; Deborah Russell; Lyndsey A Whitlock; Caroline E Ridgway; Gary J Muirhead
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

3.  Hospitalization due to adverse drug reactions and drug interactions before and after HAART.

Authors:  M M Foisy; K Gough; C M Quan; K Harris; D Ibanez; A Phillips
Journal:  Can J Infect Dis       Date:  2000-07

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  Drug interactions of HIV protease inhibitors.

Authors:  L I Malaty; J J Kuper
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

7.  Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.

Authors:  Alice Tseng; Michelle Foisy
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

Review 8.  HIV: primary and secondary prophylaxis for opportunistic infections.

Authors:  Judith Aberg; William Powderly
Journal:  BMJ Clin Evid       Date:  2010-06-28

9.  Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Authors:  Samantha Abel; Timothy M Jenkins; Lyndsey A Whitlock; Caroline E Ridgway; Gary J Muirhead
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

10.  Maraviroc: in vitro assessment of drug-drug interaction potential.

Authors:  Ruth Hyland; Maurice Dickins; Claire Collins; Hannah Jones; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2008-04-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.